FlexJointPlus

Natural health product licensed in Canada

Licence holder

J2K Interactive Inc.

NPN or DIN-HM

80116167

Status

Active licence

Licence date

5 February 2022

Revision date

20 April 2022

Form

Capsule

Route of administration

Orale

Application type

Générale (non traditionelle)

If this product were sold in France

• Dose déclarée au-delà d'une limite

  Vitamine D: up to 25 µg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).

  arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Non-medicinal ingredients

Gélatine, Silice, farine de riz, Stéarate de magnésium

Recommended doses in Canada

Uses authorised in Canada

Text supplied in English because no French text is available.

Source of/Provides antioxidants. Helps maintain healthy calcium metabolism. Calcium intake, when combined with sufficient Vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. Helps (to) maintain/support immune function. Helps in the absorption (and use) of calcium and phosphorus. Helps in the development and maintenance of bones and teeth. Helps to build strong bones and teeth. Helps to prevent vitamin D deficiency. Helps with immune function. Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise in post-menopausal women. Helps to minimize discomfort due to moderate intensity aerobic exercise in postmenopausal women. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise. Helps to minimize discomfort due to moderate intensity aerobic exercise. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise. (NEM) Starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. (NEM is) Clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days). (NEM) Helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80116167

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated 20 April 2022 (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2022. Photograph the packaging to check whether it has changed.

Has the product changed? Photograph the packaging.